Non-Hodgkin-Lymphome (NHL)

Diffuses großzelliges B-Zell-Lymphom

GO41944/ StarGlo

  • Status: nicht rekrutierend, NCT04408638
  • A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Kurzinformation
  • Ansprechpartner:
    Prof. Dr. Gerald Illerhaus (Leiter der Klinischen Prüfung)
    Telefon: 0711 278-30401
    E-Mail: g.illerhaus@klinikum-stuttgart.de
  • Studienzentrale
    Telefon: 0711 278-30410, -30411, -30414
    E-Mail: scc-studienzentrale@klinikum-stuttgart.de

Pola-R-ICE

  • Status: aktiv, NCT04833114
  • An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with diffuse large B-cell lymphoma (DLBCL) at first progression or relapse
  • Kurzinformation
  • Ansprechpartner:
    Prof. Dr. Gerald Illerhaus
    Telefon: 0711 278-30401
    E-Mail: g.illerhaus@klinikum-stuttgart.de
  • Studienzentrale
    Telefon: 0711 278-30410, -30411, -30414
    E-Mail: scc-studienzentrale@klinikum-stuttgart.de